127 related articles for article (PubMed ID: 38291692)
1. Effectiveness of strategies to suppress antibodies to infliximab in pediatric inflammatory bowel disease.
Jagt JZ; Holleman KW; Benninga MA; Van Limbergen JE; de Boer NKH; de Meij TGJ
J Pediatr Gastroenterol Nutr; 2024 Jan; 78(1):57-67. PubMed ID: 38291692
[TBL] [Abstract][Full Text] [Related]
2. High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases.
Sasson AN; Ananthakrishnan AN
Dig Dis Sci; 2022 Jul; 67(7):3124-3128. PubMed ID: 34117949
[TBL] [Abstract][Full Text] [Related]
3. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.
Brandse JF; Mould D; Smeekes O; Ashruf Y; Kuin S; Strik A; van den Brink GR; DʼHaens GR
Inflamm Bowel Dis; 2017 Apr; 23(4):650-660. PubMed ID: 28195852
[TBL] [Abstract][Full Text] [Related]
4. Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.
Zitomersky N; Chi L; Liu E; Bray KR; Papamichael K; Cheifetz AS; Snapper SB; Bousvaros A; Silvester JA
J Pediatr Gastroenterol Nutr; 2024 Feb; 78(2):261-271. PubMed ID: 38374555
[TBL] [Abstract][Full Text] [Related]
5. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.
Pallagi-Kunstár É; Farkas K; Szepes Z; Nagy F; Szűcs M; Kui R; Gyulai R; Bálint A; Wittmann T; Molnár T
World J Gastroenterol; 2014 May; 20(17):5031-5. PubMed ID: 24833846
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.
Papamichael K; Vajravelu RK; Osterman MT; Cheifetz AS
Dig Dis Sci; 2018 Mar; 63(3):761-767. PubMed ID: 29340807
[TBL] [Abstract][Full Text] [Related]
7. Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Hofmekler T; Bertha M; McCracken C; Martineau B; McKinnon E; Schoen BT; McElhanon BO; Tenjarla G; Kugathasan S; Sauer CG
J Pediatr Gastroenterol Nutr; 2017 Apr; 64(4):580-585. PubMed ID: 28079601
[TBL] [Abstract][Full Text] [Related]
8. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases.
Van Stappen T; Billiet T; Vande Casteele N; Compernolle G; Brouwers E; Vermeire S; Gils A
Inflamm Bowel Dis; 2015 Sep; 21(9):2172-7. PubMed ID: 26284296
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
Marini JC; Sendecki J; Cornillie F; Popp JW; Black S; Blank M; Gils A; Van Stappen T; Hamann D; Rispens T; Thérien L; Chun K; Shankar G
AAPS J; 2017 Jan; 19(1):161-171. PubMed ID: 27600137
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
[TBL] [Abstract][Full Text] [Related]
11. Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD.
Lega S; Phan BL; Rosenthal CJ; Gordon J; Haddad N; Pittman N; Benkov KJ; Dubinsky MC
Inflamm Bowel Dis; 2019 Jan; 25(1):134-141. PubMed ID: 29868777
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.
Battat R; Lukin D; Scherl EJ; Pola S; Kumar A; Okada L; Yang L; Jain A; Siegel CA
Inflamm Bowel Dis; 2021 Aug; 27(9):1443-1451. PubMed ID: 33252119
[TBL] [Abstract][Full Text] [Related]
15. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
[TBL] [Abstract][Full Text] [Related]
16. Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort.
Azzam N; Aljebreen A; Alharbi O; Charabaty A; Alanazi M; Alkuwaykibi N; Alfaraidi J; Bashamil A; Almansour T; Almadi M
Arab J Gastroenterol; 2021 Mar; 22(1):66-72. PubMed ID: 33632623
[TBL] [Abstract][Full Text] [Related]
17. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.
Nanda KS; Cheifetz AS; Moss AC
Am J Gastroenterol; 2013 Jan; 108(1):40-7; quiz 48. PubMed ID: 23147525
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.
Guidi L; Pugliese D; Panici Tonucci T; Berrino A; Tolusso B; Basile M; Cantoro L; Balestrieri P; Civitelli F; Bertani L; Marzo M; Felice C; Gremese E; Costa F; Viola F; Cicala M; Kohn A; Gasbarrini A; Rapaccini GL; Ruggeri M; Armuzzi A
J Crohns Colitis; 2018 Aug; 12(9):1079-1088. PubMed ID: 29860436
[TBL] [Abstract][Full Text] [Related]
19. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease.
Choi SY; Kang B; Lee JH; Choe YH
Gut Liver; 2017 Jan; 11(1):55-61. PubMed ID: 27609485
[TBL] [Abstract][Full Text] [Related]
20. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
